Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology’s 63rd Annual Scientific Session

Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology’s 63rd Annual Scientific Session

[PR Newswire] – THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ — Amgen (AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody th more

View todays social media effects on AMGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Amgen is hiring next, click here to view

Share this post

Comments (0)